Clear and achieved alignment w/FDA...filing of BLA in EU & multiple countries in 2010...Q1(10) FDA submission.....Q3(10) pot approval...less than 50% of Allopurinol patients reach target of <6mg/dL @ 300mg & tophi resolution takes YEARS.... vs only a few weeks for K...1/3 of Febux.patients drop out due to adverse events and 1/3 are not controlled (SUA<6) w/Febux 80mg...2/3 failing Allop also failed Febux.....slide 20 showed complete tophi resolution w/K......the fact that K's patient profile had 7 flares/yr vs only 1.6 Febux P3 and *84% of SVNT's patients had pre-existing serious CV disease prior to study and a 70% hypertension rate and mean of 8.6 concomitant co-morbidities vs only 0-2 comorbit for 70% of P3 febux patients AND that K STILL...was able to...... "WITHIN 24 HOURS OF INFUSION".... REDUCE URIC ACID LEVELS TO 1-2 mg/dL ,AND...SHOW COMPLETE tophi resolution after only 2 weeks IMHO speaks volumes. In summary, SVNT did not go up today on foolish takeover rumors but rather on EXTREMELY SOLID.... fundementals and data points that will very likely and soon lead to an actual takeover and not rumors of one. 100k-170k est US orphan patients times $10k-$20k/yr. K will likely be a $2B+ drug worldwide.